Collplant issues letter to shareholders

Rehovot, israel , feb. 15, 2024 /prnewswire/ -- collplant biotechnologies (nasdaq:  clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its chief executive officer, yehiel tal. view as pdf dear shareholders, as we look toward a promising and exciting year ahead, i am proud to reflect on collplant's main achievements throughout 2023.
CLGN Ratings Summary
CLGN Quant Ranking